Kris Cameron Wood
Associate Professor of Pharmacology and Cancer Biology
Our laboratory uses genomic and pharmacological approaches to understand how tumor dependencies are shaped by cell intrinsic factors, environmental factors, and drug treatments during the dynamic process of tumor evolution. To learn more, please visit our laboratory website: https://woodlabduke.com/.Appointments and Affiliations
- Associate Professor of Pharmacology and Cancer Biology
- Associate Professor of Cell Biology
- Core Faculty in Innovation & Entrepreneurship
- Member of the Duke Cancer Institute
Contact Information
- Email Address: kris.wood@duke.edu
- Websites:
Education
- Ph.D. Massachusetts Institute of Technology, 2007
Courses Taught
- UPGEN 778A: University Program in Genetics and Genomics Biological Solutions Module I
- PHARM 818: Molecular Mechanisms of Oncogenesis
- PHARM 495: Research Independent Study
- PHARM 494: Research Independent Study
- PHARM 493: Research Independent Study
- PHARM 394: Research Independent Study
- PHARM 393: Research Independent Study
- MOLCAN 818: Molecular Mechanisms of Oncogenesis
- CMB 710E: Cell & Molecular Biology Module V
- CMB 710B: Cell & Molecular Biology Module II
In the News
- Locking Leukemia's Cellular Escape Hatch (Jun 7, 2022 | Pratt)
- Cancer Repair Mechanism Could Be Potential Drug Target (Mar 31, 2022 | Duke Health News)
- Cancer Therapy Using Genetic Targeting and Gel Delivery Shows Promise (Sep 16, 2019 | Pratt School of Engineering)
- From Innovation to Impact (Oct 3, 2018 | Duke Med Alumni News)
- Faculty Startup Sold to Belgian Pharma for $30 Million (Apr 9, 2018)
- Why Do Perfectly Good Cancer Treatments Suddenly Stop Working? (Oct 25, 2017 | Duke Cancer Institute)
- The Challenges of Combating Cancer Drug Resistance (Nov 18, 2015 | Duke Research Blog)
- Researchers Map Paths to Cancer Drug Resistance (Jan 4, 2015 | Duke Today)
Representative Publications
- Gilmer, TM; Lai, C-H; Guo, K; Deland, K; Ashcraft, KA; Stewart, AE; Wang, Y; Fu, J; Wood, KC; Kirsch, DG; Kastan, MB, A novel dual ATM/DNA-PK inhibitor, XRD-0394, potently radiosensitizes and potentiates PARP and topoisomerase I inhibitors., Mol Cancer Ther (2024) [10.1158/1535-7163.MCT-23-0890] [abs].
- Killarney, ST; Tait, SWG; Green, DR; Wood, KC, Sublethal engagement of apoptotic pathways in residual cancer., Trends Cell Biol, vol 34 no. 3 (2024), pp. 225-238 [10.1016/j.tcb.2023.07.005] [abs].
- Maltas, J; Killarney, ST; Singleton, KR; Strobl, MAR; Washart, R; Wood, KC; Wood, KB, Drug dependence in cancer is exploitable by optimally constructed treatment holidays., Nat Ecol Evol, vol 8 no. 1 (2024), pp. 147-162 [10.1038/s41559-023-02255-x] [abs].
- Maltas, J; Killarney, ST; Singleton, KR; Strobl, MAR; Washart, R; Wood, KC; Wood, KB, Author Correction: Drug dependence in cancer is exploitable by optimally constructed treatment holidays., Nat Ecol Evol, vol 8 no. 1 (2024) [10.1038/s41559-023-02300-9] [abs].
- Wood, K; Nussbaum, D; Martz, C; Waters, A; Barrera, A; Rutter, J; Cerda-Smith, C; Stewart, A; Wu, C; Cakir, M; Levandowski, C; Kantrowitz, D; McCall, S; Pierobon, M; Petricoin, E; Smith, J; Der, C; Taatjes, D, Mediator Kinase Inhibition Impedes Transcriptional Plasticity and Prevents Resistance to ERK/MAPK-Targeted Therapy in KRAS-Mutant Cancers. (2023) [10.21203/rs.3.rs-3511242/v1] [abs].